Haase, Detlef

[["dc.bibliographiccitation.firstpage","820"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","829"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Luno, Elisa"],["dc.contributor.author","Cervera, Jose"],["dc.contributor.author","Granada, Isabel"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Steidl, Christian"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Faderl, Stefan"],["dc.contributor.author","Pierce, Sherry"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:12:21Z"],["dc.date.available","2018-11-07T09:12:21Z"],["dc.date.issued","2012"],["dc.description.abstract","Purpose The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the International Prognostic Scoring System (IPSS) in 1997, knowledge concerning the prognostic impact of abnormalities has increased substantially. The present study proposes a new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients. Patients and Methods Patients were included from the German-Austrian MDS Study Group (n = 1,193), the International MDS Risk Analysis Workshop (n = 816), the Spanish Hematological Cytogenetics Working Group (n = 849), and the International Working Group on MDS Cytogenetics (n = 44) databases. Patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only were evaluated for overall survival (OS) and AML evolution. Internal validation by bootstrap analysis and external validation in an independent patient cohort were performed to confirm the results. Results In total, 19 cytogenetic categories were defined, providing clear prognostic classification in 91% of all patients. The abnormalities were classified into five prognostic subgroups (P < .001): very good (median OS, 61 months; hazard ratio [HR], 0.5; n = 81); good (49 months; HR, 1.0 [reference category]; n = 1,809); intermediate (26 months; HR, 1.6; n = 529); poor (16 months; HR, 2.6; n = 148); and very poor (6 months; HR, 4.2; n = 187). The internal and external validations confirmed the results of the score. Conclusion In conclusion, these data should contribute to the ongoing efforts to update the IPSS by refining the cytogenetic risk categories. J Clin Oncol 30: 820-829. (C) 2012 by American Society of Clinical Oncology"],["dc.identifier.doi","10.1200/JCO.2011.35.6394"],["dc.identifier.isi","000302626600017"],["dc.identifier.pmid","22331955"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26930"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Deitken, Sven"],["dc.contributor.author","Seraphin, Joerg"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Bruemmendorf, Tim Henrik"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Boehme, Angelika"],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T08:36:46Z"],["dc.date.available","2018-11-07T08:36:46Z"],["dc.date.issued","2010"],["dc.format.extent","1211"],["dc.identifier.isi","000289662203269"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18387"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","52nd Annual Meeting of the American-Society-of-Hematology (ASH)"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","841"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","850"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.date.accessioned","2018-11-07T08:39:26Z"],["dc.date.available","2018-11-07T08:39:26Z"],["dc.date.issued","2010"],["dc.description.abstract","Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a substantial risk of progression to acute myeloid leukemia (AML). For many years, the main treatment option for MDS was best supportive care which alleviates symptoms, but has no effect on the natural course of the disease. Recently, demethylating agents have become available as a promising new treatment for patients with MDS. In two randomized clinical trials, the demethylating agent azacitidine has demonstrated a reduced risk of transformation to AML, improvement of peripheral blood values, an improved quality of life, and a definite survival advantage compared to conventional care regimens for patients with International Prognostic Scoring System score of intermediate-2 or high-risk MDS. This review aims to provide practical recommendations for the use of azacitidine and the management of its side effects in patients with MDS, assuring safe administration and best efficacy of treatment."],["dc.description.sponsorship","German Kompetenznetz \"Akute and chronische Leukamien\""],["dc.identifier.doi","10.1007/s00277-010-1015-0"],["dc.identifier.isi","000280226700001"],["dc.identifier.pmid","20567826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18997"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.title","Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","900"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","906"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Götze, Katharina S."],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","Seraphin, Jörg"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Böhme, Angelika"],["dc.contributor.author","Schmidt, Burkhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:22:10Z"],["dc.date.available","2018-11-07T09:22:10Z"],["dc.date.issued","2013"],["dc.description.abstract","The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Celgene(R) Germany"],["dc.identifier.doi","10.1016/j.leukres.2013.03.019"],["dc.identifier.isi","000321111900012"],["dc.identifier.pmid","23623559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0145-2126"],["dc.title","Molecular cytogenetic monitoring from CD34+peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","902"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","910"],["dc.bibliographiccitation.volume","128"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Sanz, Guillermo F."],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Garcia-Manero, Guillermo"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Bowen, David"],["dc.contributor.author","Fenaux, Pierre"],["dc.contributor.author","Dreyfus, Francois"],["dc.contributor.author","Kantarjian, Hagop M."],["dc.contributor.author","Kuendgen, Andrea"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Cazzola, Mario"],["dc.contributor.author","Cermak, Jaroslav"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Levis, Alessandro"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Maciejewski, Jaroslaw P."],["dc.contributor.author","Machherndl-Spandl, Sigrid"],["dc.contributor.author","Magalhaes, Silvia M. M."],["dc.contributor.author","Miyazaki, Yasushi"],["dc.contributor.author","Sekeres, Mikkael A."],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Tauro, Sudhir"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Vallespi, Teresa"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Greenberg, Peter L."],["dc.date.accessioned","2018-11-07T10:10:07Z"],["dc.date.available","2018-11-07T10:10:07Z"],["dc.date.issued","2016"],["dc.description.abstract","In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower-and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making."],["dc.description.sponsorship","MDS Foundation, Inc."],["dc.identifier.doi","10.1182/blood-2016-02-700054"],["dc.identifier.isi","000383834800008"],["dc.identifier.pmid","27335276"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39793"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Time-dependent changes in mortality and transformation risk in MDS"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2709"],["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","2716"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Kroenke, Jan"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Jensen, Kai-Ole"],["dc.contributor.author","Tschuertz, Florian"],["dc.contributor.author","Corbacioglu, Andrea"],["dc.contributor.author","Gaidzik, Verena I."],["dc.contributor.author","Paschka, Peter"],["dc.contributor.author","Onken, Shiva"],["dc.contributor.author","Eiwen, Karina"],["dc.contributor.author","Habdank, Marianne"],["dc.contributor.author","Spaeth, Daniela"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Wattad, Mohammed"],["dc.contributor.author","Kindler, Thomas"],["dc.contributor.author","Salih, Helmut R."],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Nachbaur, David"],["dc.contributor.author","von Lilienfeld-Toal, Marie"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Mergenthaler, Hans-Guenther"],["dc.contributor.author","Krauter, Juergen"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Goehring, Gudrun"],["dc.contributor.author","Schlegelberger, Brigitte"],["dc.contributor.author","Doehner, Hartmut"],["dc.contributor.author","Doehner, Konstanze"],["dc.date.accessioned","2018-11-07T08:54:49Z"],["dc.date.available","2018-11-07T08:54:49Z"],["dc.date.issued","2011"],["dc.description.abstract","Purpose To evaluate the prognostic value of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) with NPM1 mutation (NPM1(mut)). Patients and Method RNA-based real-time quantitative polymerase chain reaction (RQ-PCR) specific for the detection of six different NPM1(mut) types was applied to 1,682 samples (bone marrow, n = 1,272; blood, n = 410) serially obtained from 245 intensively treated younger adult patients who were 16 to 60 years old. Results NPM1(mut) transcript levels as a continuous variable were significantly associated with prognosis after each treatment cycle. Achievement of RQ-PCR negativity after double induction therapy identified patients with a low cumulative incidence of relapse (CIR; 6.5% after 4 years) compared with RQ-PCR-positive patients (53.0%; P < .001); this translated into significant differences in overall survival (90% v 51%, respectively; P = .001). After completion of therapy, CIR was 15.7% in RQ-PCR-negative patients compared with 66.5% in RQ-PCR-positive patients (P < .001). Multivariable analyses after double induction and after completion of consolidation therapy revealed higher NPM1(mut) transcript levels as a significant factor for a higher risk of relapse and death. Serial post-treatment assessment of MRD allowed early detection of relapse in patients exceeding more than 200 NPM1(mut)/10(4) ABL copies. Conclusion We defined clinically relevant time points for NPM1(mut) MRD assessment that allow for the identification of patients with AML who are at high risk of relapse. Monitoring of NPM1(mut) transcript levels should be incorporated in future clinical trials to guide therapeutic decisions. J Clin Oncol 29:2709-2716. (C) 2011 by American Society of Clinical Oncology"],["dc.description.sponsorship","German Jose Carreras Leukemia-Foundation [DJCLS 06/06v]"],["dc.identifier.doi","10.1200/JCO.2011.35.0371"],["dc.identifier.isi","000292210500025"],["dc.identifier.pmid","21555683"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22758"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.relation.issn","0732-183X"],["dc.title","Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Heuser, Michael"],["dc.contributor.author","Meggendorfer, Manja"],["dc.contributor.author","Cruz, Michelle Maria Araujo"],["dc.contributor.author","Koehler, Larissa"],["dc.contributor.author","Goehring, Gudrun"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Gutermuth, Annika"],["dc.contributor.author","Panagiota, Victoria"],["dc.contributor.author","Fabisch, Jana"],["dc.contributor.author","Haferlach, Claudia"],["dc.contributor.author","Koenecke, Christian"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Thiede, Christian"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Schroeder, Thomas"],["dc.contributor.author","Kobbe, Guido"],["dc.contributor.author","Ehrlich, Steve"],["dc.contributor.author","Stamer, Kathrin"],["dc.contributor.author","Schlegelberger, Brigitte"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Thol, Felicitas"],["dc.date.accessioned","2018-11-07T09:31:24Z"],["dc.date.available","2018-11-07T09:31:24Z"],["dc.date.issued","2014"],["dc.identifier.isi","000349233800125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31530"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","56th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","722A"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","723A"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Kendgen, Andrea"],["dc.contributor.author","Mende, Claudia"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Fischer, Stephanie"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Haas, Rainer"],["dc.contributor.author","Gattermann, Norbert"],["dc.contributor.author","Germing, Ulrich"],["dc.date.accessioned","2018-11-07T10:52:32Z"],["dc.date.available","2018-11-07T10:52:32Z"],["dc.date.issued","2007"],["dc.identifier.isi","000251100803233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49134"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","49th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0006-4971"],["dc.title","Prognostic factors in treatment-related Myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML)."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Mueller, Thomas"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Gattermann, Norbert"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Krieger, Otto"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Steidl, Christian"],["dc.date.accessioned","2018-11-07T08:57:36Z"],["dc.date.available","2018-11-07T08:57:36Z"],["dc.date.issued","2006"],["dc.format.extent","79A"],["dc.identifier.isi","000242440000253"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23435"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.eventlocation","Orlando, FL"],["dc.relation.issn","0006-4971"],["dc.title","Evidence for an underestimation of the prognostic impact of poor cytogenetics within the IPSS."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","929"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","930"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Sole, Francesc"],["dc.contributor.author","del Mar Mallo, Maria"],["dc.contributor.author","Steidl, Christian"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Noesslinger, Thomas"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Andersen, Mette K."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T11:09:04Z"],["dc.date.available","2018-11-07T11:09:04Z"],["dc.date.issued","2008"],["dc.identifier.isi","000262104703128"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52928"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","0006-4971"],["dc.title","New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]